Fulgent Genetics Inc(FLGT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.83 | Insider Own | 36% | Shs Outstand | 27.5M | Perf Week | 8.45% |
| Market Cap | 0.60B | Forward P/E | - | EPS next Y | 39.21% | Insider Trans | -0.12% | Shs Float | 17.6M | Perf Month | -1.54% |
| Enterprise Value | 0.34B | PEG | - | EPS next Q | -0.65 | Inst Own | 57.28% | Short Float | 12.11% | Perf Quarter | 31% |
| Income | -0.08B | P/S | 1.84 | EPS this Y | -640.48% | Inst Trans | -10.89% | Short Ratio | 6.98 | Perf Half Y | 42.73% |
| Sales | 0.32B | P/B | 0.6 | EPS next 5Y | - | ROA | -7.37% | Short Interest | 2.13M | Perf YTD | -17.47% |
| Book/sh | 36.4 | P/C | 2.32 | EPS past 3/5Y | - | ROE | -7.97% | 52W High | -30.15% ($31.04) | Perf Year | -4.62% |
| Cash/sh | 9.34 | P/FCF | - | Sales past 3/5Y | -19.52% -5.21% | ROIC | -8.37% | 52W Low | 61.07% ($13.46) | Perf 3Y | -9.78% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -69.59% | Gross Margin | 32.9% | Volatility(W/M) | 3.08% 4.2% | Perf 5Y | -73.85% |
| Dividend TTM | - | EV/Sales | 1.06 | Sales Y/Y TTM | 6.83% | Oper. Margin | -36.06% | ATR (14) | 0.76 | Perf 10Y | 138.5% |
| Dividend Ex-Date | - | Quick Ratio | 6.33 | EPS Q/Q | -69.92% | Profit Margin | -26.05% | RSI (14) | 58.27 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.34 | Sales Q/Q | 4.38% | SMA20 | 3.96% ($20.85) | Beta | 0.99 | Target Price | $19 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/11/5 | SMA50 | 4.46% ($20.75) | Rel Volume | 0.69 | Prev Close | $21.52 |
| Employees | 1344 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -26.09% -9.16% | SMA200 | 11.7% ($19.41) | Avg Volume(3M) | 0.31M | Price | $21.68 |
| IPO | 2016/9/29 | Option/Short | Yes/Yes | Trades | 2978 | Volume | 210,296 | Change | 0.74% |
🧬 Fulgent Genetics (FLGT) is a U.S. diagnostics and testing company with genetic testing at its core. It offers a broad range of genetic diagnostic services using its proprietary technology platform, and has recently been expanding into the therapeutics segment by developing new anticancer drugs. Its defining feature is this dual structure that combines diagnostics with new drug development.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
Next earnings report: November 5
6 days to go.
FLGT has a sound balance sheet but weak earning power
Of every $100 in sales, $36.06 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -640.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $184. Peers typically go for $458. Compared with its own 1-year average, it is 52% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -73.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 57.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #32 of 44 in the industry
Based on market cap of $597M.
OPK#29 Opko Health Inc $1B PER - 
CSTL#30 Castle Biosciences Inc $1B PER - 
MYGN#31 Myriad Genetics Inc $638M PER - FLGT#32 Fulgent Genetics Inc $597M PER - 
BDSX#33 Biodesix Inc $261M PER - 
FAQ
What kind of company is FLGT?
FLGT belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of FLGT?
The market cap of FLGT is approximately $597M, ranking 3,017 within its sector.
What is the 52-week high and low for FLGT?
FLGT has recorded a 52-week high of $31.04 and a low of $13.46.
